share_log

Vanda Pharmaceuticals Q2 EPS $0.05 Misses $0.11 Estimate, Sales $64.40M Miss $67.00M Estimate

Vanda Pharmaceuticals Q2 EPS $0.05 Misses $0.11 Estimate, Sales $64.40M Miss $67.00M Estimate

萬達製藥第二季度每股收益0.05美元未達到0.11美元預期，銷售額6440萬美元未達到6700萬美元預期
Benzinga Real-time News ·  2022/08/03 16:30

Vanda Pharmaceuticals (NASDAQ:VNDA) reported quarterly earnings of $0.05 per share which missed the analyst consensus estimate of $0.11 by 54.55 percent. This is a 70.59 percent decrease over earnings of $0.17 per share from the same period last year. The company reported quarterly sales of $64.40 million which missed the analyst consensus estimate of $67.00 million by 3.88 percent. This is a 5.15 percent decrease over sales of $67.90 million the same period last year.

萬達製藥(納斯達克：VNDA)公佈季度收益為每股0.05美元，低於分析師一致預期的0.11美元，增幅為54.55%。這比去年同期每股0.17美元的收益下降了70.59%。該公司公佈季度銷售額為6,440萬美元，低於分析師一致預期的6,700萬美元，降幅為3.88%。這比去年同期6790萬美元的銷售額下降了5.15%。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論